Lipella Pharmaceuticals Inc. (LIPO): R&D Expense
Not updated since 2024-12-31. No annual report in US GAAP has been filed since. Companies that switch to IFRS reporting, as many foreign filers do, or stop filing are not updated here.
$3.61M
Year ended 2024-12-31
$3.57M
Trailing 12 months to 2025-09-30
+35.4%
3-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2024-12-31 | $3.61M | +18.9% | 2025-03-28, From 2024-01-01 |
| 2023-12-31 | $3.04M | +19.3% | 2025-03-28, From 2023-01-01 |
| 2022-12-31 | $2.55M | +74.9% | 2024-02-27, From 2022-01-01 |
| 2021-12-31 | $1.46M | n/a | 2023-03-31, From 2021-01-01 |